Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EHA 2020 | Prevalence of BTK and PLCγ2 mutations in CLL relapsing under ibrutinib

Paolo Ghia • 21 Jun 2020
EHA 2020
Chronic Lymphocytic Leukemia Leukemia Ibrutinib

Paolo Ghia, MD, of the Università Vita-Salute San Raffaele, Milan, Italy, discusses an ERIC study evaluating the incidence of BTK and PLCγ2 (phospholipase C Gamma 2) mutations in ibrutinib refractory chronic lymphocytic leukemia (CLL) patients. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Paolo Ghia

Updates to the ESMO CLL clinical practice guidelines: implications for relapsed disease 19:55
Updates to the ESMO CLL clinical practice guidelines: implications for relapsed disease
Arnon Kater et al. • 25 Apr 2025
A study investigating the efficacy of CAR-T therapy in Richter’s transformation 1:52
A study investigating the efficacy of CAR-T therapy in Richter’s transformation
Paolo Ghia • 27 Sep 2024
A study investigating outcomes for a rare subgroup of CLL with CNS involvement 2:17
A study investigating outcomes for a rare subgroup of CLL with CNS involvement
Paolo Ghia • 27 Sep 2024
The future of CLL treatment: aiming for long-lasting remission 1:42
The future of CLL treatment: aiming for long-lasting remission
Paolo Ghia • 27 Sep 2024

Related Videos

The value and mission of the International Workshop on Acute Leukemias 14:36
The value and mission of the International Workshop on Acute Leukemias
Charles Craddock et al. • 21 Oct 2025
One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years? 1:30
One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years?
Koichi Takahashi • 26 Sep 2025
One big question with Naval Daver: what AML advance could transform frontline care in three years? 1:05
One big question with Naval Daver: what AML advance could transform frontline care in three years?
Naval Daver • 26 Sep 2025
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years? 3:13
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years?
Charles Craddock • 26 Sep 2025
The content of VJHemOnc is intended for healthcare professionals